Osaka, Japan

Chiaki Migihashi

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Dainippon Pharma Co., Ltd.. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chiaki Migihashi. Retrieved from https://idiyas.com/inventor/chiaki-migihashi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chiaki Migihashi: Innovator in Pharmaceutical Chemistry

Introduction

Chiaki Migihashi is a notable inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative research and development of new compounds.

Latest Patents

Chiaki holds a patent for a compound known as 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. This invention is represented by a specific formula and aims to provide new therapeutic options in the pharmaceutical industry.

Career Highlights

Chiaki Migihashi is currently employed at Sumitomo Dainippon Pharma Co., Ltd. Her work at this esteemed company has allowed her to focus on developing novel pharmaceutical compounds that can potentially improve patient outcomes.

Collaborations

Chiaki has collaborated with several talented individuals in her field, including Akihito Fujii and Kazumi Niidome. These partnerships have fostered a collaborative environment that enhances innovation and research.

Conclusion

Chiaki Migihashi's contributions to pharmaceutical chemistry exemplify the impact of innovative research in developing new therapeutic compounds. Her work continues to inspire advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…